Fig. 2From: Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomideObinutuzumab induces higher rate of cell death compared to rituximab in MCL cell lines. Cell death of MCL cell lines (JeKo -1, REC-1), treated with CD20-ab [rituximab, obinutuzumab (1 µM)] and co-cultured with PBMC. Data shown are mean values ± standard deviation of cell death from three individual experiments compared to control (no anti-CD20 mAb). a JeKo-1, b REC-1. RTX rituximab, OBZ obinutuzumab. Results were compared with student t-test. * = p<0.05Back to article page